Clonz lights a beacon of hope for many patients worldwide
March 15th, 2022
Clonz lights a beacon of hope for many patients worldwide with its accessible drug positioning and launch of new R&D labs in the Genome valley outside Hyderabad.
Clonz, operational since 2010 has specific technology and methodology which will be boosted with the launch of a state of the art MABs R&D labs.
Clonz’s mission emphasizes bioengineering and creating biosimilars that improve accessibility for patients worldwide. To achieve this, they employ in house clone/product development with complete understanding and control over processes to ensure robust manufacturing. The founders are among the most respected long standing MABs focused developers in India.
This experienced scientific team of recognized leaders in biosimilar research and manufacturing will manufacture several biosimilars which will be phased into various global markets in the coming decade. Clonz philosophy places emphasis on knowledge and experience with increased understanding of MABs in-depth and improving efficiency and speed of production. It is a total package that gives efficiency, quality and holds out much hope for improving many lives.
Contact us to find out more
Clonz biotech was founded in 2010 by an experienced team of recognized leaders in biosimilar research and manufacturing.